CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 7 No. 10
 

NCI Sets Sail on a New Tack In the Stormy Seas of CAM

October 1, 1998

WASHINGTON--The National Cancer Institute is getting more comfortable with the idea of seriously evaluating complementary and alternative medicine (CAM) approaches to treating cancer.

NCI director Richard D. Klausner, MD, told a congressional committee that the Institute plans to (1) undertake a series of studies to evaluate CAM cancer treatments; (2) formally designate an NCI coordinator of CAM therapies; (3) strengthen its relationship with the NIH’s Office of Alternative Medicine (OAM), including the formation of a joint cancer advisory panel (CAP-CAM); and (4) provide the public with an unprecedented flow of accurate information on complementary and alternative medicine.

"Let me emphasize at the start that the basic tenet of the NIH is to employ rigorous methodologies to reach conclusions based on evidence and not on belief," he said at a hearing of the House Government and Reform Oversight Committee. "Standards of evidence cannot be compromised, and I am pleased that, on this crucial point, I and many colleagues in the complementary and alternative medicine community agree."

He gave two reasons for NCI’s expanding relationship with CAM advocates: The need to be open to new ideas and new approaches and the fact that "many people take complementary and alternative medicines, and they reasonably ask who is providing evidence as to whether they help, do nothing, or are harmful."

Dr. Klausner noted that NCI supports many "high-quality" CAM-related research efforts in cancer. These include studies of diet interventions in cancer treatment and the potential therapeutic value of vitamins and minerals in cancer therapy and prevention; trials of stress and pain management to enhance patients’ quality of life; and investigations of the effect of natural inhibitors of carcinogenesis. Such research will be expanded to even more controversial areas, he said.

NCI to Appoint CAM Coordinator

The appointment of a coordinator for CAM therapies, a new position at NCI, is in its final stages, the director said. The new coordinator will be a member of the cancer research community and will develop relations with the CAM community and serve as a liaison between the two groups "to encourage collaboration and joint research initiatives."

NCI and OAM are currently developing a list of potential members for CAP-CAM, the advisory panel on complementary and alternative medicine in cancer. The 13-member panel will consist of a broad range of experts from conventional and CAM cancer research.

"This group will review and evaluate summaries of evidence for CAM cancer claims submitted by practitioners, make recommendations to OAM and NCI on whether and how these evaluations should be followed up, and be available to observe and provide advice about those studies supported by OAM and NCI, and about communication of the results of those studies," Dr. Klausner said.

NCI is also revamping the way it presents information on CAM to the public. "Several months ago, as a result of our own concerns and the constructive input from the CAM community, we removed from the NCI website all previous CAM information and are creating new information that treats CAM dispassionately and fairly," Dr. Klausner said.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy